6:00 p.m. CET – Adocia (Euronext Paris: FR0011184241 – ADOC), the clinical-stage biopharmaceutical company specializing in the development of innovative peptide and protein formulations for the treatment of diabetes and other metabolic diseases, today announces its participation in virtual investor conferences.
Members of Adocia’s management team will be available for virtual meetings: Gérard Soula (CEO), Olivier Soula (Deputy CEO) and Valérie Danaguezian (CFO and Administration).
• 25th ODDO BHF Forum
Date: January 6-11, 2022
Link: https://conferences.oddo-bhf.com/index.aspx
• French delegation @ JP Morgan Healthcare Conference
Date: January 10-13, 2022
Link: https://www.jpmorgan.com/solutions/cib/insights/health-care-conference
• Biotech Showcase
Date: January 10–12 and January 17–19, 2022
Link: https://informaconnect.com/biotech-showcase/?gclid=Cj0KCQiA8ICOBhDmARIsAEGI6o31OJhl9HkuWr0UvHw6OxlXr3i2J42j_-dvnYmiyuhzE7rwMr_BEALRUaAlNcNc
• HC Wainwright BIOCONNECT Virtual 2022 Conference
Date: January 10-13, 2022
Link: https://hcwevents.com/bioconnect/